266
Participants
Start Date
November 1, 2006
Primary Completion Date
May 10, 2012
Study Completion Date
April 1, 2013
Panitumumab
6mg/kg IV
Bevacizumab
Either 5mg/kg OR 10mg/kg IV
Leucovorin
400mg/m\^2 IV (in the vein)
Irinotecan
180mg/m\^2 IV (in the vein)
5-Fluorouracil
400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects
Lead Sponsor
Amgen
INDUSTRY